Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer

Akebia Therapeutics, Inc.

CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.
CEO John Butler will serve as interim principal financial officer starting Transition Date.
Separation agreement provides 12 months base salary, COBRA premium reimbursement, continued equity vesting.
Severance conditioned on general release of claims and compliance with non-compete and non-solicitation terms.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

John Butler

interim principal financial officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-03-22
Filed: March 15, 2024, 7:59 PM ET

John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.

Departed

Ellen Snow

Senior Vice President, Chief Financial Officer and Treasurer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-03-22
Successor: John Butler
Filed: March 15, 2024, 7:59 PM ET

On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Butler was appointed as interim principal financial officer at Akebia Therapeutics, Inc..

Action: appointed
Role: interim principal financial officer

Exact text from the filing

John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ellen Snow changed role as Senior Vice President, Chief Financial Officer and Treasurer at Akebia Therapeutics, Inc..

Action: transitioned
Role: Senior Vice President, Chief Financial Officer and Treasurer

Exact text from the filing

On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-069123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.